Reported Earnings • Mar 17
Full year 2025 earnings released: EPS: ₩471 (vs ₩479 in FY 2024) Full year 2025 results: EPS: ₩471 (down from ₩479 in FY 2024). Revenue: ₩36.0b (down 2.9% from FY 2024). Net income: ₩7.37b (down 5.0% from FY 2024). Profit margin: 21% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Ankündigung • Feb 20
BIT Computer Co., Ltd, Annual General Meeting, Mar 26, 2026 BIT Computer Co., Ltd, Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: seminar room, 33, seocho-daero 74-gil, seocho-gu, seoul South Korea Reported Earnings • Nov 20
Third quarter 2025 earnings released: EPS: ₩107 (vs ₩124 in 3Q 2024) Third quarter 2025 results: EPS: ₩107 (down from ₩124 in 3Q 2024). Revenue: ₩8.45b (flat on 3Q 2024). Net income: ₩1.67b (down 17% from 3Q 2024). Profit margin: 20% (down from 24% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Declared Dividend • Nov 08
Dividend of ₩63.00 announced Dividend of ₩63.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 17th April 2026 Dividend yield will be 1.3%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased over the past 6 years and payments have been stable during that time. Earnings per share has grown by 1.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Nov 07
BIT Computer Co., Ltd announces Annual dividend, payable on April 17, 2026 BIT Computer Co., Ltd announced Annual dividend of KRW 63.0000 per share payable on April 17, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Buy Or Sell Opportunity • May 07
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 6.3% to ₩5,270. The fair value is estimated to be ₩4,298, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 15%. Buy Or Sell Opportunity • Apr 16
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 4.2% to ₩5,240. The fair value is estimated to be ₩4,096, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 15%. Reported Earnings • Mar 14
Full year 2024 earnings released: EPS: ₩479 (vs ₩338 in FY 2023) Full year 2024 results: EPS: ₩479 (up from ₩338 in FY 2023). Revenue: ₩37.1b (up 11% from FY 2023). Net income: ₩7.76b (up 40% from FY 2023). Profit margin: 21% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Ankündigung • Feb 20
BIT Computer Co., Ltd, Annual General Meeting, Mar 25, 2025 BIT Computer Co., Ltd, Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, 33, seocho-daero 74-gil, seocho-gu, seoul South Korea Buy Or Sell Opportunity • Jan 23
Now 20% undervalued Over the last 90 days, the stock has risen 2.2% to ₩4,875. The fair value is estimated to be ₩6,099, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has grown by 6.7%. Upcoming Dividend • Dec 20
Upcoming dividend of ₩63.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 17 April 2025. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (1.1%). New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩76.9b market cap, or US$54.1m). Buy Or Sell Opportunity • Dec 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.5% to ₩4,770. The fair value is estimated to be ₩6,064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has grown by 6.7%. Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩124 (vs ₩61.00 in 3Q 2023) Third quarter 2024 results: EPS: ₩124 (up from ₩61.00 in 3Q 2023). Revenue: ₩8.43b (up 11% from 3Q 2023). Net income: ₩2.02b (up 102% from 3Q 2023). Profit margin: 24% (up from 13% in 3Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩82.7b market cap, or US$62.9m). Buy Or Sell Opportunity • Aug 19
Now 22% overvalued Over the last 90 days, the stock has fallen 6.2% to ₩5,760. The fair value is estimated to be ₩4,707, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.4% over the last 3 years. Earnings per share has declined by 5.1%. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩4,740, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 24x in the Healthcare Services industry in Asia. Total loss to shareholders of 53% over the past three years. Reported Earnings • Mar 21
Full year 2023 earnings released: EPS: ₩338 (vs ₩296 in FY 2022) Full year 2023 results: EPS: ₩338 (up from ₩296 in FY 2022). Revenue: ₩33.5b (down 4.8% from FY 2022). Net income: ₩5.54b (up 14% from FY 2022). Profit margin: 17% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 10% per year. Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩6,880, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 27x in the Healthcare Services industry in Asia. Total loss to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩8,380, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 29x in the Healthcare Services industry in Asia. Total loss to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩7,760, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 32x in the Healthcare Services industry in Asia. Total loss to shareholders of 16% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩61.00 per share at 1.0% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 17 April 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.8%). Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩61.00 (vs ₩71.00 in 3Q 2022) Third quarter 2023 results: EPS: ₩61.00 (down from ₩71.00 in 3Q 2022). Revenue: ₩7.63b (up 2.3% from 3Q 2022). Net income: ₩998.4m (down 15% from 3Q 2022). Profit margin: 13% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Buying Opportunity • Oct 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be ₩6,185, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Earnings per share has declined by 10%. Reported Earnings • May 19
First quarter 2023 earnings released: EPS: ₩139 (vs ₩63.00 in 1Q 2022) First quarter 2023 results: EPS: ₩139 (up from ₩63.00 in 1Q 2022). Revenue: ₩7.53b (down 11% from 1Q 2022). Net income: ₩2.29b (up 122% from 1Q 2022). Profit margin: 30% (up from 12% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 24
Full year 2022 earnings released: EPS: ₩296 (vs ₩294 in FY 2021) Full year 2022 results: EPS: ₩296 (up from ₩294 in FY 2021). Revenue: ₩35.1b (down 3.6% from FY 2021). Net income: ₩4.87b (flat on FY 2021). Profit margin: 14% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩7,480, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 39x in the Healthcare Services industry in Asia. Total returns to shareholders of 27% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩61.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 19 April 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.4%). Buying Opportunity • Dec 06
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 4.8%. The fair value is estimated to be ₩7,561, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 4.1%. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Chairman & CEO Hyun-Jung Cho was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improved over the past week After last week's 19% share price gain to ₩5,940, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 15% share price gain to ₩6,930, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 56% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₩6,850, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 38x in the Healthcare Services industry in Asia. Total returns to shareholders of 45% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Chairman & CEO Hyun-Jung Cho was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improved over the past week After last week's 15% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 46x in the Healthcare Services industry in Asia. Total returns to shareholders of 95% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩61.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 08 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.2%). Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 36% share price gain to ₩11,400, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 44x in the Healthcare Services industry in Asia. Total returns to shareholders of 140% over the past three years. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩8,900, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 50x in the Healthcare Services industry in Asia. Total returns to shareholders of 56% over the past three years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩9,150, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 49x in the Healthcare Services industry in Asia. Total returns to shareholders of 28% over the past three years. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS ₩394 (vs ₩431 in FY 2019) The company reported a poor full year result with weaker earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: ₩37.3b (flat on FY 2019). Net income: ₩6.47b (down 8.7% from FY 2019). Profit margin: 17% (down from 19% in FY 2019). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 26
New 90-day low: ₩9,240 The company is down 25% from its price of ₩12,250 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 12% over the same period. Ankündigung • Feb 09
BIT Computer Co., Ltd, Annual General Meeting, Mar 23, 2021 BIT Computer Co., Ltd, Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₩10,750, the stock is trading at a trailing P/E ratio of 29.7x, down from the previous P/E ratio of 37.7x. This compares to an average P/E of 69x in the Healthcare Services industry in Asia. Total returns to shareholders over the past three years are 96%. Valuation Update With 7 Day Price Move • Dec 07
Market bids up stock over the past week After last week's 16% share price gain to ₩13,700, the stock is trading at a trailing P/E ratio of 37.8x, up from the previous P/E ratio of 32.7x. This compares to an average P/E of 77x in the Healthcare Services industry in Asia. Total returns to shareholders over the past three years are 143%. Is New 90 Day High Low • Dec 04
New 90-day high: ₩13,050 The company is up 8.0% from its price of ₩12,100 on 04 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 6.0% over the same period. Valuation Update With 7 Day Price Move • Nov 19
Market bids up stock over the past week After last week's 31% share price gain to ₩12,800, the stock is trading at a trailing P/E ratio of 29x, up from the previous P/E ratio of 22.1x. This compares to an average P/E of 72x in the Healthcare Services industry in Asia. Total returns to shareholders over the past three years are 136%. Is New 90 Day High Low • Oct 19
New 90-day low: ₩9,720 The company is down 17% from its price of ₩11,700 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,833 per share. Is New 90 Day High Low • Sep 24
New 90-day low: ₩10,250 The company is down 19% from its price of ₩12,600 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,740 per share. Ankündigung • Jun 30
BIT Computer Co., Ltd (KOSDAQ:A032850) agreed to acquire Jaincom Co., Ltd. for KRW 6 billion BIT Computer Co., Ltd (KOSDAQ:A032850) agreed to acquire Jaincom Co., Ltd. for KRW 6 billion on June 29, 2020. As per terms of transaction, BIT Computer Co., Ltd will acquire 340,000 shares of Jaincom Co., Ltd. Consideration for the acquisition will be in cash. For the year ended, December 31, 2019, Jaincom Co., Ltd. reported sales of KRW 3,714 million, total assets of KRW 3,754 million and net income of KRW 513 million. Transaction is expected to be complete on July 10, 2020. 
